Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Other 1

Conditions

Mucositis 4Hematologic Neoplasms 3Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Sarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphopenia 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Graft vs Host Disease 1Cytopenia 1Chondrosarcoma 1Bone Neoplasms 1Anemia 1

Interventions

Cyclophosphamide 64Tacrolimus 55Methotrexate 46Mycophenolic Acid 39Cyclosporine 37fludarabine phosphate 35Busulfan 35Antilymphocyte Serum 32fludarabine 29Sirolimus 26Melphalan 23Peripheral Blood Stem Cell Transplantation 22Radiotherapy 21Methylprednisolone 21Whole-Body Irradiation 19Filgrastim 17thymoglobulin 14Thiotepa 11Stem Cell Transplantation 10Rituximab 10ruxolitinib 9Granulocyte Colony-Stimulating Factor 9Prednisone 7Hematopoietic Stem Cell Transplantation 7Etoposide 7Cord Blood Stem Cell Transplantation 7Alemtuzumab 7Transplantation 6Pentostatin 6Cytarabine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Graft vs Host Disease × angiotensin I (1-7) × Clear all
NCT01882387 2016-08-31

Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Tarix Pharmaceuticals

Phase 2 Withdrawn
OtherOther hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡